January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.
Chemoimmunotherapy Combos “Game-Changing” in Frontline Metastatic NSCLC
October 30th 2020Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.